ISSUE: New medical technologies that prolong life result in additional health care use in life years gained. Currently, many health technology assessment (HTA) guidelines recommend that “unrelated future costs” of a medical technology are excluded from an appraisal (so the costs of caring for a patient’s dementia after preventing their death from stroke would not be included in a cost effectiveness analysis of thrombolysis treatment). Recently, Dutch guidelines for HTA have changed and recommend inclusion of future unrelated medical costs. This begs the question whether other HTA guidelines should also recommend inclusion of future unrelated medical costs? OVERVIEW: The panelists will present and discuss the pros and cons of including future unrelated costs in HTA. Alec Morton will summarize theoretical arguments for and against inclusion of future unrelated medical costs. Pieter van Baal will discuss how these costs can be estimated in practice. Finally, Ad Antonisse will present the industry point of view. The audience will be invited to participate in the discussion whether HTA guidelines should recommend inclusion of future unrelated medical costs.